Home ETF List About

Portfolio Holdings Detail for ISIN IE000G2LIHG9
Stock Name / FundiShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerSAUA(EUR) ETF Plus

Holdings detail for INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc) INCY holdings

DateNumber of INCY Shares HeldBase Market Value of INCY SharesLocal Market Value of INCY SharesChange in INCY Shares HeldChange in INCY Base ValueCurrent Price per INCY Share HeldPrevious Price per INCY Share Held
2025-09-25 (Thursday)45,710USD 3,732,679USD 3,732,679
2025-09-24 (Wednesday)45,680USD 3,844,429USD 3,844,429
2025-09-18 (Thursday)45,103INCY holding increased by 120USD 3,878,858INCY holding increased by 64300USD 3,878,858120USD 64,300 USD 86 USD 84.8
2025-09-17 (Wednesday)44,983INCY holding increased by 150USD 3,814,558INCY holding increased by 53069USD 3,814,558150USD 53,069 USD 84.8 USD 83.9
2025-09-16 (Tuesday)44,833INCY holding increased by 240USD 3,761,489INCY holding increased by 54027USD 3,761,489240USD 54,027 USD 83.9 USD 83.14
2025-09-15 (Monday)44,593USD 3,707,462USD 3,707,462
2025-09-12 (Friday)44,513USD 3,699,030USD 3,699,030
2025-09-11 (Thursday)44,513INCY holding decreased by -10USD 3,835,685INCY holding decreased by -4424USD 3,835,685-10USD -4,424 USD 86.17 USD 86.25
2025-09-10 (Wednesday)44,523INCY holding increased by 640USD 3,840,109INCY holding increased by 83724USD 3,840,109640USD 83,724 USD 86.25 USD 85.6
2025-09-09 (Tuesday)43,883INCY holding increased by 44USD 3,756,385INCY holding decreased by -38319USD 3,756,38544USD -38,319 USD 85.6 USD 86.56
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE000G2LIHG9

Show aggregate share trades of INCY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-18BUY120 86.000* 68.96
2025-09-17BUY150 84.800* 68.88
2025-09-16BUY240 83.900* 68.80
2025-09-11SELL-10 86.170* 68.71 Profit of 687 on sale
2025-09-10BUY640 86.250* 68.62
2025-09-09BUY44 85.600* 68.53
2025-08-06BUY226 77.650* 68.43
2025-07-31BUY65 74.890* 68.35
2025-07-29BUY260 77.375* 68.25
2025-07-28BUY48 70.160* 68.24
2025-07-25BUY78 70.200* 68.23
2025-07-24BUY38 70.490* 68.22
2025-07-23BUY91 70.690* 68.20
2025-07-22BUY52 68.900* 68.20
2025-07-18BUY88 67.860* 68.20
2025-07-17BUY78 68.940* 68.20
2025-07-11BUY104 68.590* 68.18
2025-07-10BUY117 70.340* 68.17
2025-07-09BUY117 68.720* 68.16
2025-07-07SELL-78 67.270* 68.17 Profit of 5,317 on sale
2025-07-02SELL-325 68.170* 68.17 Profit of 22,155 on sale
2025-06-27BUY39 68.370* 68.17
2025-06-26BUY39 70.810* 68.15
2025-06-24SELL-182 69.010* 68.15 Profit of 12,403 on sale
2025-06-18BUY104 68.270* 68.15
2025-06-17BUY39 68.810* 68.15
2025-06-16SELL-53 71.220* 68.13 Profit of 3,611 on sale
2025-06-13BUY114 67.750* 68.13
2025-06-12SELL-65 69.220* 68.12 Profit of 4,428 on sale
2025-06-11BUY143 68.850* 68.12
2025-06-06BUY39 68.770* 68.09
2025-06-05BUY182 67.240* 68.10
2025-06-04BUY24 67.420* 68.10
2025-06-03SELL-12 67.110* 68.11 Profit of 817 on sale
2025-05-30SELL-1,464 65.060* 68.15 Profit of 99,767 on sale
2025-05-29BUY36 66.040* 68.16
2025-05-27BUY204 65.350* 68.20
2025-05-23BUY180 64.245* 68.26
2025-05-22BUY84 64.510* 68.29
2025-05-19BUY72 63.810* 68.37
2025-05-16BUY36 63.310* 68.40
2025-05-15SELL-24 62.760* 68.45 Profit of 1,643 on sale
2025-05-14BUY12 61.160* 68.50
2025-05-13BUY24 60.810* 68.56
2025-05-08BUY24 59.730* 68.62
2025-05-07BUY36 59.550* 68.69
2025-05-02BUY1,332 62.530* 68.86
2025-04-30BUY420 62.660* 68.97
2025-04-29BUY108 60.430* 69.04
2025-04-28BUY84 59.520* 69.11
2025-04-25BUY216 59.160* 69.19
2025-04-24SELL-252 58.970* 69.28 Profit of 17,458 on sale
2025-04-23BUY228 58.000* 69.37
2025-04-22BUY96 57.380* 69.47
2025-04-17BUY132 58.210* 69.77
2025-04-15BUY120 58.460* 69.97
2025-04-11BUY208 56.870* 70.19
2025-04-09BUY72 58.860* 70.42
2025-04-08BUY432 56.970* 70.55
2025-04-07BUY144 60.290* 70.64
2025-04-04SELL-192 60.580* 70.73 Profit of 13,581 on sale
2025-04-02BUY1,632 62.330* 70.81
2025-04-01BUY12 60.910* 70.90
2025-03-31BUY84 60.550* 71.00
2025-03-28BUY48 60.600* 71.10
2025-03-27BUY24 60.680* 71.20
2025-03-26BUY12 61.260* 71.30
2025-03-25BUY132 62.080* 71.39
2025-03-24BUY156 62.780* 71.48
2025-03-21SELL-48 61.920* 71.58 Profit of 3,436 on sale
2025-03-20BUY192 60.580* 71.69
2025-03-19BUY36 60.340* 71.81
2025-03-18BUY432 60.000* 71.93
2025-03-17BUY84 62.010* 72.03
2025-03-14BUY624 67.860* 72.08
2025-03-13BUY120 67.710* 72.12
2025-03-12SELL-600 67.730* 72.17 Profit of 43,303 on sale
2025-03-11SELL-444 68.070* 72.22 Profit of 32,064 on sale
2025-03-10BUY132 71.130* 72.23
2025-03-07BUY24 70.790* 72.25
2025-03-05BUY180 69.810* 72.27
2025-03-04BUY204 69.680* 72.30
2025-03-03BUY384 70.260* 72.33
2025-02-28BUY312 73.500* 72.31
2025-02-27SELL-60 73.180* 72.30 Profit of 4,338 on sale
2025-02-25BUY444 74.400* 72.25
2025-02-21BUY48 72.110* 72.23
2025-02-18SELL-108 71.270* 72.28 Profit of 7,807 on sale
2025-02-14SELL-732 70.420* 72.33 Profit of 52,947 on sale
2025-02-13BUY12 70.010* 72.36
2025-02-12BUY118 69.050* 72.41
2025-02-07SELL-17 74.130* 72.53 Profit of 1,233 on sale
2025-02-06BUY228 74.950* 72.49
2025-02-05BUY60 75.260* 72.45
2025-02-04BUY72 74.120* 72.43
2025-02-03BUY72 73.740* 72.41
2025-01-31BUY132 74.160* 72.38
2025-01-29SELL-12 73.720* 72.34 Profit of 868 on sale
2025-01-28SELL-108 73.150* 72.33 Profit of 7,811 on sale
2025-01-27SELL-192 72.640* 72.32 Profit of 13,886 on sale
2025-01-24BUY144 72.590* 72.32
2025-01-23BUY24 72.530* 72.31
2025-01-22BUY197 72.410* 72.31
2025-01-21BUY144 73.470* 72.29
2025-01-16BUY221 72.470* 72.30
2025-01-14BUY96 71.930* 72.30
2025-01-10BUY288 70.540* 72.34
2024-12-30BUY36 68.420* 72.53
2024-12-27BUY48 69.230* 72.60
2024-12-23BUY360 69.840* 72.81
2024-12-20BUY96 68.840* 72.91
2024-12-19BUY12 67.060* 73.06
2024-12-18BUY96 67.550* 73.20
2024-12-17BUY24 69.400* 73.30
2024-12-16BUY120 69.800* 73.40
2024-12-13BUY86 68.550* 73.54
2024-12-10BUY600 72.480* 73.60
2024-12-09BUY72 72.110* 73.65
2024-12-06SELL-180 75.920* 73.58 Profit of 13,244 on sale
2024-12-05SELL-12 74.920* 73.53 Profit of 882 on sale
2024-12-03BUY60 72.030* 73.55
2024-11-27SELL-72 75.450* 73.36 Profit of 5,282 on sale
2024-11-26BUY252 74.800* 73.30
2024-11-25BUY33 73.520* 73.29
2024-11-22SELL-24 71.720* 73.36 Profit of 1,761 on sale
2024-11-21SELL-60 70.390* 73.51 Profit of 4,411 on sale
2024-11-20SELL-24 71.050* 73.64 Profit of 1,767 on sale
2024-11-19BUY12 70.560* 73.81
2024-11-18BUY108 76.970* 73.62
2024-11-11BUY36 81.530* 72.63
2024-11-07BUY32 82.340* 71.06
2024-11-06BUY288 80.950* 70.24
2024-11-05BUY60 77.280* 69.60
2024-11-04BUY22 75.750* 68.98
2024-11-01BUY33 76.130* 68.19
2024-10-30SELL-72 73.930* 66.52 Profit of 4,789 on sale
2024-10-29SELL-216 73.600* 65.34 Profit of 14,113 on sale
2024-10-28SELL-84 65.690* 65.27 Profit of 5,483 on sale
2024-10-21SELL-12 65.270* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19321,923395451,11071.4%
2025-09-18244,9471,423469,74752.1%
2025-09-17277,858779546,95350.8%
2025-09-16359,781946576,37962.4%
2025-09-15347,4534582,22859.7%
2025-09-12353,0400631,53455.9%
2025-09-11448,7333,894739,70160.7%
2025-09-10490,727248671,93273.0%
2025-09-09515,3951,822682,79175.5%
2025-09-08308,184119479,82864.2%
2025-09-05256,7192,505512,04950.1%
2025-09-04422,6241,507834,71750.6%
2025-09-03381,6797,777624,92261.1%
2025-09-02547,12015,396816,26767.0%
2025-08-29148,294262304,42748.7%
2025-08-28164,0080347,48047.2%
2025-08-27248,926453513,40148.5%
2025-08-26365,1306709,32051.5%
2025-08-25478,1301,306642,31974.4%
2025-08-22344,3522,023596,30157.7%
2025-08-21198,7294,881335,30159.3%
2025-08-20351,6993,977555,34563.3%
2025-08-19343,1103,146574,32859.7%
2025-08-18366,1244,996653,10356.1%
2025-08-15480,8858,035625,79776.8%
2025-08-14593,55436,654806,06873.6%
2025-08-13845,18198,1601,257,50367.2%
2025-08-12462,89642,208678,68968.2%
2025-08-11385,211696595,89264.6%
2025-08-08248,925738426,18758.4%
2025-08-07268,864929420,48663.9%
2025-08-06554,642891731,48475.8%
2025-08-05361,6872,092623,87958.0%
2025-08-04338,0051,464519,15065.1%
2025-08-01414,814828572,87972.4%
2025-07-31570,8456,148777,41773.4%
2025-07-30471,30314,166881,19453.5%
2025-07-29966,64010,5811,593,70160.7%
2025-07-28382,23662625,51061.1%
2025-07-25216,96749422,99051.3%
2025-07-24348,27623528,51765.9%
2025-07-23297,903583487,29761.1%
2025-07-22267,987172446,48960.0%
2025-07-21223,626380406,72955.0%
2025-07-18241,218108471,58951.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.